Previous 10 | Next 10 |
home / stock / slncf / slncf news
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will r...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, Pres...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P....
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, Pres...
Silence Therapeutics Plc (SLNCF) Q2 2020 Results Conference Call September 14, 2020 8:00 AM ET Company Participants Gem Hopkins - Head, IR and Corporate Communications Iain Ross - Chairman Mark Rothera - President & CEO Giles Campion - Head of R&D and Chief Medical O...
Silence Therapeutics ( OTCPK:SLNCF ) appoints Mark Rothera as President and CEO, effective immediately. More news on: Orchard Therapeutics plc, Silence Therapeutics plc, Healthcare stocks news, Read more ...
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2020 Q2 earnings Read more ...
Silence Therapeutics plc (SLNCF) Q4 2019 Earnings Conference Call April 14, 2020 8:00 AM ET Company Participants Iain Ross – Interim Executive Chairman Rob Quinn – Chief Financial Officer Conference Call Participants Miles Dixon – Peel Hunt Nathaniel Ca...
Mallinckrodt (NYSE: MNK ) inks an agreement with British biotech Silence Therapeutics ( OTCPK:SLNCF ) securing exclusive global rights to preclinical-stage SLN500, a C3-targeting RNAi therapeutic candidate plus options to in-license up to two additional complement-targeted assets in Sile...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...